search icon
      blog search icon

      Histogen Inc. (HSTO) stock caused an incline in premarket – What’s going on? - Stocks Telegraph

      By Mahrukh Rehan

      Published on

      December 3, 2021

      1:53 PM UTC

      Histogen Inc. (HSTO) stock caused an incline in premarket – What’s going on? - Stocks Telegraph

      Histogen Inc. (HSTO) has seen an incline of 5.01% in the premarket. However, the last trading session closed at $0.4352 with a decline of 2.68%.

      Third Quarter 2021 Business Updates – Latest news by HSTO

      On 10th November 2021, HSTO announced the third quarter of 2021 business updates. HSTO began a Phase 1/2 clinical research of HST 003 in June 2021 to assess the safety and effectiveness of the human extracellular matrix. Moreover, the company kept moving forward with the efforts to assess other pipeline options. In addition, preclinical proof-of-concept investigations are now underway, with preliminary results expected in the fourth quarter of 2021. The company also announced the start of a strategic partnership process with partner Amerimmune to further the development of emricasan in COVID-19 patients with mild to moderate symptoms.

      CEO Transition by HSTO – All About it

      HSTO reported on 8th November 2021 that Steven J. Mento has been appointed as the Executive Chairman and Interim President and Chief Executive Officer of the company. Dr. Mento was a co-founder of Conatus and served as the company’s president and CEO from July 2005 until the merger. Moreover, he has worked in the biotechnology and pharmaceutical sectors for over 35 years in a variety of senior managerial and scientific roles.

      Now what?

      HSTO is sure that they have the cutting-edge technology, patented procedures, and the proper strategy to be a leader in restorative treatments. However, the company also intends to add value to the portfolio of caspases by continuing to develop it. They are confident that Steve’s previous leadership expertise and track record will ensure a smooth transfer at this time.

      HSTO and Amerimmune to present data in COVID

      On 2nd November 2021, HSTO announced that Amerimmune will provide updated results from the emricasan Phase 1 research in mildly symptomatic COVID-19 patients. In a small group of COVID-19 patients who received orally-dosed emricasan, the Phase 1 study revealed outstanding safety in early-stage, moderately symptomatic patients.

      When compared to the placebo group, Emricasan reduced clinical symptoms and accelerated recovery from COVID-19. Furthermore, Amerimmune’s first identification of disease-related indicators allowed HSTO to concentrate on learning how the virus impacts the immune system.

      More From Stocks telegraph